HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the first patient in the Phase I/II clinical trial with ...

HYOGO, Japan, December 20, 2024--(BUSINESS WIRE)--JCR Pharmaceuticals Co., Ltd. (TSE 4552; "JCR") today announced that the first patient has been dosed in the Phase III clinical trial of JR-142 ...

Barbieri discovered the problem while receiving training on the JLTV at Oshkosh Defense, which designs, produces and sustains military vehicles. Cpl. Gage Barbieri received a Meritorious Service ...

HYOGO, Japan--(BUSINESS WIRE)--MEDIPAL HOLDINGS CORPORATION (TSE 7459 “MEDIPAL”) and JCR Pharmaceuticals Co., Ltd. (TSE 4552 “JCR”) today announced the completion of the regulatory review ...

TOKYO & HYOGO, Japan, May 07, 2025--(BUSINESS WIRE)--MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) today announced that the U.S. Food and Drug ...

Oshkosh Defense was awarded the hotly-contested initial contract to build the JLTV in 2015 and has since produced in excess of 19,000 of the armored vehicles. When the initial $6.7 billion ...

In its bid to develop epilepsy treatments that can overcome the notoriously tricky blood-brain barrier, Angelini Pharma has pledged to pay JCR Pharmaceuticals over $500 million in biobucks.

U.S. Sen. Tammy Baldwin is urging the U.S. Army to reconsider its decision to award AM General an $8.7 billion contract to build the military's Joint Light Tactical Vehicle. In a letter sent to ...

Two airmen drove a JLTV for an operational mission in western Nebraska to support launch facility maintenance near the town of Harrisburg, located about 15 miles east of the Nebraska-Wyoming ...